Exchange: NASDAQ·Updated 04:44 PM EST

About FULC

About

Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company, which develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015, and is headquartered in Cambridge, MA.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
55

Frequently Asked Questions

Advertisement|Remove ads.